RxDoctor Payments Data

Kyra Hughes, NP

Nurse Practitioner · Fishers, INNPI 1891340394

Payments from drug & device makers

$4,408in general payments, 2019–2025

Across 209 payments — averaging $21.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$708
  • GSK$530
  • Novartis$436
  • Amgen$418
  • AbbVie$324
  • Johnson & Johnson$291
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$4,07592%
  • Education$3338%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,408 in reported general payments places this provider in the 90th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$43,902
Medicare patients
111
Services billed
6,691

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab32$218,960
Enbrel SureclickEtanercept24$176,547
RinvoqUpadacitinib23$148,175
Cimzia (2 Pack)Certolizumab Pegol14$87,926
Orencia ClickjectAbatacept15$85,266
XolairOmalizumab27$76,599
Hydroxychloroquine Sulfate98$4,119
Arnuity ElliptaFluticasone Furoate17$3,718
Leflunomide27$3,419
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$1,745
MethotrexateMethotrexate Sodium76$1,609
Albuterol Sulfate HfaAlbuterol Sulfate29$1,335
Azelastine Hcl25$984
Fluticasone Propionate36$572
Montelukast Sodium57$549

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$324$148,17523 claims
UCB, Inc.Cimzia (2 Pack)$130$87,92614 claims
GSKArnuity Ellipta$530$3,71817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Fishers

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →